Novo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 34%
By Annika Kim Constantino
Novo Nordisk split puts Hims & Hers future in question
By Anjalee Khemlani
The Weight Loss Drug Market Has Gotten Messy. What to Know.
By Josh Nathan-kazis
Novo, Hims & Hers engage in war of words after Wegovy deal falls apart
By Stine Jacobsen & Amina Niasse
Novo Nordisk: End to Telehealth Collaboration, Mixed Amylin Data Weigh on Valuation
By Karen Andersen
Full Coverage of this storyNovo Nordisk A/S (NVO): “How Could They Be So Far Behind?,” Wonders Jim Cramer
By Ramish Cheema
Full Coverage of this storyNovo Nordisk's New Obesity Drug Beats Wegovy Weight Loss in Early Trial
By Dominic Chopping
Dual-Target Weight Loss Treatment Shows Promise
By Megan Brooks
Novo's injectable amycretin yet to hit weight loss plateau, suggesting Zepbound-beating potential
Novo Nordisk's experimental drug results in up to 24% weight loss
By Deena Beasley
Experimental drug helps patients lose nearly a quarter of body weight in early trials
By Melissa Rudy
Full Coverage of this storyNovo Nordisk Faces Spain Probe Over Weight-Loss Advertising
By Elliot Burrin
Novo Nordisk questioned over controversial Spanish obesity awareness campaign
Novo Nordisk Faces Spanish Probe Over Weight-Loss Advertising
By Elliot Burrin
Novo Nordisk Under Probe by Spanish Health Ministry Over Advertising of Weigh-Loss Drug
‘Obesity can kill’: Controversial campaign by Ozempic drugmaker sparks backlash
By Jessica Mouzo
Full Coverage of this storyNovo Nordisk Stock Tumbles on CagriSema Trial Data. Why Investors Have Doubts.
By Mackenzie Tatananni
Why Shares in Novo Nordisk Lost Weight Today
By Lee Samaha
Novo Nordisk shares fall as obesity pipeline faces investor scrutiny
By Maggie Fick & Stine Jacobsen
Novo Nordisk Stock Sinks as Latest Weight-Loss Drug Trial Disappoints
By Aaron McDade
Novo Nordisk, seen as lagging in obesity drug race, says it’s playing the long game
By Elaine Chen
Full Coverage of this storyNovo Nordisk launches weight-loss drug Wegovy in India to compete with Lilly's Mounjaro
By Kashish Tandon & Rishika Sadam
Can 2 blockbuster weight loss injectables, Wegovy & Mounjaro, fight India’s obesity curve? Listen in to the experts
By Anonna Dutt
Wegovy enters India: Experts discuss health impact of the popular weight loss drug
A big fat fight has just broken out in India
Novo Nordisk Launches Weight-Loss Drug Wegovy, Months After Lilly, in Obesity-Hit India
By Satviki Sanjay
Full Coverage of this storyHow Novo Nordisk will lose billions because it didn't pay $250
By Steve Goldstein
A $250 mistake seems set to cost Ozempic maker Novo Nordisk billions
By Benjamin Kesslen
Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee
By Jason Ma
Could a Novo error set up early GLP-1 generics in Canada?
Novo Nordisk patent lapse opens door for Canadian Ozempic generics
By Marisa Woutersen
Full Coverage of this storyUS judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list
By Diana Novak Jones
Lilly's Antibody Protects Patients From Losing Muscle While Taking Novo's Wegovy
By Tristan Cesar Manalac
Activist hedge fund builds stake in Ozempic-maker Novo Nordisk
By Oliver Barnes & Hannah Kuchler
NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm
How Ozempic’s Maker Lost Its Grip on the Obesity Market It Created
By Peter Loftus & Noémie Bisserbe
Novo Nordisk's former chief makes comeback to steer choice of new CEO
By Jacob Gronholt & Maggie Fick
Cigna announces new deal for copay caps on Eli Lilly and Novo Nordisk weight loss drugs
By Bertha Coombs
EPO revokes another Novo Nordisk patent behind Ozempic and Wegovy drugs
By Konstanze Richter
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a year
By Catherine Baab-Muguira
Novo Nordisk strikes $2.2 billion deal with Septerna to develop new obesity treatments
By Stine Jacobsen
Is Novo Nordisk Stock a Buy?
By Eric Volkman
Novo Nordisk Is Getting Absolutely Destroyed
By Victor Tangermann
Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance
By Ashley Capoot & Annika Kim Constantino
Novo Nordisk CEO Lars Fruergaard Jorgensen to Steps Down
By Dominic Chopping & Peter Loftus
Novo Nordisk gains rights to novel small molecule inhibitor
By Catherine Eckford
Novo Nordisk Financial Report Reveals Monlunabant Failure But Several Bright Spots for Kidney Disease
By Charlotte Robinson
Novo Seeks FDA Nod for Semaglutide Pill as Oral Obesity Space Heats Up
By Tristan Cesar Manalac
Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
By Abigail Beaney
'Not a cost-cutting exercise': Novo Nordisk CSO explains rationale behind pharma's R&D shake-up
By James Waldron
Novo Nordisk has goals to cut workplace stress. Here's how it plans to achieve it
By Charlotte Edmond
Novo Nordisk Extends Lowered Wegovy Price to Retail Pharmacies
By Denise Myshko
Novo Nordisk using AI to treat chronic diseases
By Alex Devereson
BE&K to build $4.1B Novo Nordisk facility in North Carolina
By Zachary Phillips